Literature DB >> 9551918

Distinct patterns of folding and interactions with calnexin and calreticulin in human class I MHC proteins with altered N-glycosylation.

Q Zhang1, R D Salter.   

Abstract

Calnexin is a lectin-like chaperone that binds to class I MHC molecules soon after their synthesis, retaining unassembled heavy chains and also assisting their folding. Following association with beta2-microglobulin (beta2m) in the endoplasmic reticulum, a large proportion of human class I molecules release from calnexin, whereas mouse class I molecules do not. We asked whether addition of a second N-glycan to the human class I molecule A*0201 at position 176, a site present in mouse, would affect its binding to calnexin. The 176dg mutant with N-glycans at positions 86 and 176, when transfected into CIR cells, demonstrated increased binding to calnexin, detectable both before and after association with beta2m, and reduced interaction with calreticulin and TAP relative to wild-type protein bearing a single N-glycan at position 86. Cell surface levels of the mutant were decreased only slightly relative to the wild type, suggesting that the protein is not misfolded or grossly altered structurally. A subpopulation of mutant molecules was retained in the endoplasmic reticulum, and surprisingly, these molecules reacted with w6/32, which recognizes an epitope present on transport-competent class I HLA complexes. Transfection into Daudi cells demonstrated that 176dg reacts with w6/32 in the absence of beta2m, suggesting that the Ab epitope can be induced by binding of calnexin. These data may explain previously noted differences between mouse and human class I MHC proteins and demonstrate that the location of N-oligosaccharides within proteins can influence their folding and interactions with chaperones such as calnexin and calreticulin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551918

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Pathogen evasion strategies for the major histocompatibility complex class I assembly pathway.

Authors:  Antony N Antoniou; Simon J Powis
Journal:  Immunology       Date:  2008-02-18       Impact factor: 7.397

2.  Activation of human monocyte cell line U937 via cell surface calreticulin.

Authors:  J H Cho; K J Homma; S Kanegasaki; S Natori
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

Review 3.  Role of N-oligosaccharide endoplasmic reticulum processing reactions in glycoprotein folding and degradation.

Authors:  A J Parodi
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

Review 4.  Calreticulin: one protein, one gene, many functions.

Authors:  M Michalak; E F Corbett; N Mesaeli; K Nakamura; M Opas
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

Review 5.  [Role of MHC class I molecules in anti-tumoral mechanisms in human malignant melanoma].

Authors:  J Dissemond; S Grabbe
Journal:  Hautarzt       Date:  2006-08       Impact factor: 0.751

6.  Roles of calreticulin and calnexin during mucin synthesis in LS180 and HT29/A1 human colonic adenocarcinoma cells.

Authors:  D J McCool; Y Okada; J F Forstner; G G Forstner
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

7.  Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma.

Authors:  Ping-Chiao Tsai; Francisco J Hernandez-Ilizaliturri; Naveen Bangia; Scott H Olejniczak; Myron S Czuczman
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

8.  Importance of N-linked glycosylation in the functional expression of murine CD1d1.

Authors:  Venkataraman Sriram; Claire A Willard; Jianyun Liu; Randy R Brutkiewicz
Journal:  Immunology       Date:  2007-08-28       Impact factor: 7.397

Review 9.  Orchestration of secretory protein folding by ER chaperones.

Authors:  Tali Gidalevitz; Fred Stevens; Yair Argon
Journal:  Biochim Biophys Acta       Date:  2013-03-15

Review 10.  Phagocytosis checkpoints as new targets for cancer immunotherapy.

Authors:  Mingye Feng; Wen Jiang; Betty Y S Kim; Cheng Cheng Zhang; Yang-Xin Fu; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2019-08-28       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.